- 专利标题: Methods and pharmaceutical compositions for the treatment of kidney cancer
-
申请号: US16339931申请日: 2017-10-04
-
公开(公告)号: US11052131B2公开(公告)日: 2021-07-06
- 发明人: Géraldine Siegfried , Abdel-Majid Khatib , Jean-Luc Hoepffner , Serge Evrard
- 申请人: INSERM (Institut National de la Santé et de la Recherche Médicale) , UNIVERSITE DE BORDEAUX , INSTITUT BERGONIÉ
- 申请人地址: FR Paris; FR Bordeaux; FR Bordeaux
- 专利权人: INSERM (Institut National de la Santé et de la Recherche Médicale),UNIVERSITE DE BORDEAUX,INSTITUT BERGONIÉ
- 当前专利权人: INSERM (Institut National de la Santé et de la Recherche Médicale),UNIVERSITE DE BORDEAUX,INSTITUT BERGONIÉ
- 当前专利权人地址: FR Paris; FR Bordeaux; FR Bordeaux
- 代理机构: Nixon & Vanderhye
- 优先权: EP16306312 20161005,EP17305507 20170504
- 国际申请: PCT/EP2017/075134 WO 20171004
- 国际公布: WO2018/065440 WO 20180412
- 主分类号: A61K38/22
- IPC分类号: A61K38/22 ; A61P35/00 ; C07K14/575
摘要:
Disclosed are methods and pharmaceutical compositions for the treatment of kidney cancer. The inventors showed that while Elabela (ELA) is mostly expressed in kidney, its expression is reduced in human kidney cancer. In a xenograft animal model (sub-cutaneous, or sub-capsular injection) Ela inhibits tumor progression. In particular, there is disclosed a method of treating kidney cancer in a subject in need thereof including administering to the subject a therapeutically effective amount of an ELA polypeptide including an amino acid sequence having at least 90% of identity with SEQ ID NO: 1 (QRPVNLTMRRKLRKHNCLQRRCMPLHSRVPFP) wherein the arginine residue (R) at position 9, 10, 20 or 21 is optionally mutated.
公开/授权文献
信息查询
IPC分类: